Bortezomib-induced severe hepatitis in multiple myeloma: a case report
- PMID: 15738379
- DOI: 10.1001/archinte.165.4.464
Bortezomib-induced severe hepatitis in multiple myeloma: a case report
Abstract
Bortezomib is a novel proteasome inhibitor with significant antimyeloma activity. Its toxicity is manageable, and the most frequent adverse effects mainly consist of gastrointestinal symptoms, peripheral neuropathy, neuropatic pain, and thrombocytopenia. Severe liver toxicity has not been previously recognized. A patient with relapsed multiple myeloma who developed bortezomib-induced severe recurrent hepatitis is described. The importance of recognizing this rare potential toxicity is highlighted in order to discontinue this agent if liver adverse reaction is suspected.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
